Biotech Stocks Rise After Hours Following Trial News and Strategic Developments
Cyclerion Therapeutics Surge: Cyclerion Therapeutics, Inc. (CYCN) saw a 48.01% increase in after-hours trading after announcing a strategic relaunch focused on neuropsychiatric therapies, including a licensing agreement with MIT for its treatment-resistant depression program, with a Phase 2 trial expected to start in 2026.
Clearside Biomedical Updates: Clearside Biomedical Inc. (CLSD) rose 6.82% in after-hours trading following presentations at the EURETINA Congress regarding its Phase 2b trial for wet age-related macular degeneration, with the next key milestone being the initiation of a Phase 3 trial.
Reviva Pharmaceuticals Conference Participation: Reviva Pharmaceuticals Holdings Inc. (RVPH) experienced an 11.50% rise in after-hours trading ahead of its participation in the Lytham Partners Fall 2025 Investor Conference, despite a decline during regular trading hours.
Corcept Therapeutics Data Presentation: Corcept Therapeutics Inc. (CORT) gained 4.54% in after-hours trading and announced it will present late-breaking data from its Phase 3 trial for relacorilant in ovarian cancer at the 2025 ESMO Annual Meeting, with key PDUFA dates set for late 2025 and mid-2026.
Trade with 70% Backtested Accuracy
Analyst Views on CYCN
About CYCN
About the author
AZZ Inc Reports Q3 Earnings Beat, Shares Rise 2.1%
- Earnings Beat: AZZ Inc reported adjusted earnings of $1.52 per share for Q3, surpassing market expectations of $1.47, indicating sustained profitability that may attract more investor interest.
- Sales Growth: The company achieved sales of $425.746 million, exceeding expectations of $418.164 million, demonstrating strong market demand and further solidifying its position in the industry.
- Stock Price Surge: In pre-market trading, AZZ Inc shares rose 2.1% to $112.09, reflecting a positive market reaction to its earnings report, which could boost investor confidence in subsequent trading days.
- Optimistic Market Outlook: With improved performance, AZZ Inc is poised to continue attracting investment and enhancing its competitive edge, particularly in the context of the current economic recovery.
Alumis Inc. Shares Surge 132% After Successful Phase 3 Trial Results
- Trial Success: Alumis Inc. achieved all primary and secondary endpoints in its Phase 3 ONWARD1 and ONWARD2 trials for envudeucitinib in moderate-to-severe plaque psoriasis, resulting in a 132% surge in stock price, indicating strong market potential and investor confidence.
- Market Reaction: Following the announcement, shares skyrocketed to $19.30, reflecting a positive investor response to the clinical data, which may attract more institutional investors and further enhance the company's market capitalization.
- Industry Impact: Alumis's success provides a new treatment option in the biopharmaceutical industry, particularly in the psoriasis sector, potentially prompting other companies to increase R&D investments and drive overall industry innovation.
- Future Outlook: With the successful clinical trials, Alumis is expected to accelerate the drug's market entry, likely leading to significant revenue growth while strengthening its position in the highly competitive biopharmaceutical market.
